|
|
||||||||
Division of Tracer Kinetics, Osaka University Graduate School of Medicine, Suita, Osaka
Research Center, Nihon Medi-Physics Co., Ltd., Sodegaura, Chiba
Institute for Clinical Research, Osaka National Hospital, Chuo-ku, Osaka, Japan
Correspondence: For correspondence or reprints contact: Tsunehiko Nishimura, MD, PhD, Division of Tracer Kinetics, Osaka University Graduate School of Medicine, D9, 2-2 Yamadaoka, Suita, Osaka, 565-0871 Japan.
ABSTRACT
99mTc-4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime (HL91) was developed as a putative hypoxic reagent. This study focused on the myocardial kinetics of 99mTc-HL91 in various oxygen levels and perfusion states. Methods: The time-activity curve of 99mTc-HL91 was measured in isolated perfused rat heart after the bolus infusion. Results: 99mTc-HL91 was cleared quickly from normoxic hearts, and retention at 30 min after injection was 0.18 ± 0.02 percentage injected dose per gram of wet weight (mean ± SE; n = 6). When the concentration of oxygen bubbling through the perfusate was reduced from 100% to 50%, 20%, 5%, and 0%, retention of <99mTc-HL91 increased to 0.47 ± 0.03 (n = 5), 0.48 ± 0.03 (n = 5), 0.71 ± 0.01 (n = 5), and 0.70 ± 0.02 (n = 5), respectively (P < 0.05). Compartment analysis revealed that the trapping mechanism, which was dependent on tissue oxygen concentration, determined the retention rate. Although not retained in stunned myocardium (0.17 ± 0.02, n = 5; P = not significant), 99mTc-HL91 was significantly retained when injected before ischemia (1.06 ± 0.06, n = 5; P < 0.05). Conclusion: These results indicate that retention of 99mTc-HL91 correlates well with oxygen level in the perfusate, suggesting that the agent may be a useful marker of the severity of myocardial hypoxia.
Key Words: radioisotopes hypoxia ischemia myocardial stunning
This article has been cited by other articles:
![]() |
S.-M. Eschmann, F. Paulsen, M. Reimold, H. Dittmann, S. Welz, G. Reischl, H.-J. Machulla, and R. Bares Prognostic Impact of Hypoxia Imaging with 18F-Misonidazole PET in Non-Small Cell Lung Cancer and Head and Neck Cancer Before Radiotherapy J. Nucl. Med., February 1, 2005; 46(2): 253 - 260. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |